Guotong

Guotong (Chengdu) New Drug Technology is a specialized one-stop CRO and CDMO platform dedicated to the radiopharmaceutical and nuclear medicine industry in China. Headquartered in Beijing and Chengdu, the company provides comprehensive services across the entire drug development lifecycle, including preclinical candidate (PCC) validation, process development, pharmacokinetics, and clinical transformation. Guotong operates multiple international-standard R&D platforms and intelligent production bases in Jiangsu, Guangdong, and Sichuan, equipped to handle a wide range of isotopes for both diagnostic and therapeutic applications. As a key subsidiary of Xiantong Pharma, the company plays a critical role in accelerating the development of high-potential radioligand therapies and molecular imaging agents for oncology and neurology.